Replimune company information, Employees & Contact Information

PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma Stock Titan

Replimune Group, Inc. Shares Promising Data on RP1 and Nivolumab Combination for Acral Melanoma at ESMO Congress 2025 Quiver Quantitative

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma FinancialContent

Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs Bain Capital

Replimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 Plan Nasdaq

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 The Manila Times

44% ORR in acral melanoma — Replimune RP1 + nivolumab; median DOR 11.9 months at ESMO 2025 Stock Titan

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update TradingView

Replimune: A Misunderstood Contender In Oncolytics (NASDAQ:REPL) Seeking Alpha

Replimune Reports Promising Clinical Data for RP1 Plus Nivolumab at ASCO 2025, Highlighting Robust Responses and Safety Profile Nasdaq

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FinancialContent

Biotech Replimune's Advanced Melanoma Drug RP1 Faces Uncertain FDA Path Following Critical Meeting Stock Titan

Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma The Manila Times

Critical FDA Meeting Scheduled: Replimune's Advanced Melanoma Treatment Faces Decisive Moment Stock Titan

Replimune's Melanoma Drug Hits FDA Roadblock: Q1 Losses Widen to $86.7M as Clinical Trials Advance Stock Titan

FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection Stock Titan

FDA Grants Priority Review to Replimune's Melanoma Treatment RP1, Breakthrough Therapy Status Secured Stock Titan

Replimune Group, Inc. Announces Proposed Public Offering of $125 Million in Common Stock and Pre-Funded Warrants Quiver Quantitative

FDA Grants Type A Meeting to Discuss RP1 Plus Nivolumab in Advanced Melanoma OncLive

Path Toward Accelerated Approval of RP1 in Advanced Melanoma Remains Unclear After FDA Type A Meeting OncLive

Replimune Prepares for Type A Meeting With FDA on RP1 Dermatology Times

FDA Issues CRL for RP1 Plus Nivolumab for Advanced Melanoma OncLive

FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma Applied Clinical Trials

FDA Accepts BLA Resubmission for RP1 Plus Nivolumab in Advanced Melanoma OncLive

FDA Accepts RP1 BLA Resubmission for Advanced Melanoma Dermatology Times

Pre-BLA Meeting Successful for RP1 Combo in Anti–PD-1–Failed Melanoma CancerNetwork

FDA Grants Priority Review to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy OncLive

FDA Issues CRL to Replimune for Vusolimogene Oderparepvec With Nivolumab for Advanced Melanoma Pharmacy Times

Melanoma Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 OncLive

IGNYTE Trial Investigators Press FDA to Reconsider Replimune CRL Amid Promising Melanoma Data, Leadership Shakeup Pharmaceutical Executive

Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma OncLive

FDA Denies Approval of Vusolimogene Oderparepvec for Advanced Melanoma Dermatology Advisor

FDA Crackdown on Trial Design: What July’s CRLs to Replimune and Capricor Mean for Sponsors Applied Clinical Trials

FDA Issues CRL for Vusolimogene Oderparepvec in Advanced Melanoma AJMC

Replimune CRL Fallout: How Biopharma Leaders Should Manage a New Layer of FDA Uncertainty Pharmaceutical Executive

FDA Issues CRL for RP1 and Nivolumab in Melanoma Dermatology Times

RP1 Yields Responses in Deep/Visceral Lesions and Across Injected/Non-Injected Lesions in Advanced PD-1–Refractory Melanoma OncLive

Replimune Appoints Sushil Patel as CEO citybiz

RP1 Plus Nivolumab Represents the Next Frontier of Oncolytic Virus–Based Therapy for Melanoma OncLive

Replimune: The Rise Of Oncolytic Virus Therapies In Cancer Treatment Seeking Alpha

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors citybiz

ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City Yahoo Finance

Incyte (INCY) and Replimune (REPL) Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 StreetInsider

Replimune Appoints Christy Oliger to its Board of Directors citybiz

Tumor-Directed Oncolytic Immunotherapies Show Promise in Replimune Clinical Update Pharmacy Times

REPL Stock Price and Chart — NASDAQ:REPL TradingView